Select Publications
Journal articles
2023, 'P1117: GLOFITAMAB PLUS R-CHOP OR POLATUZUMAB VEDOTIN-R-CHP IS DELIVERABLE AND YIELDS HIGH OVERALL RESPONSE IN PATIENTS <=65 YEARS OF AGE WITH HIGH-RISK DLBCL OR HGBL: INTERIM ANALYSIS OF THE COALITION STUDY', HemaSphere, 7, pp. e8608732 - e8608732, http://dx.doi.org/10.1097/01.hs9.0000971364.86087.32
,2023, 'P1193: POLATUZUMAB, BENDAMUSTINE & RITUXIMAB (POLA-BR) EFFICACY IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (RRDLBCL) TRIAL-INELIGIBLE PATIENTS: AN AUSTRALIAN LYMPHOMA REGISTRY (LARDR) STUDY', HemaSphere, 7, pp. e24670ab - e24670ab, http://dx.doi.org/10.1097/01.hs9.0000971668.24670.ab
,2023, 'S261: FIRST IN HUMAN DATA OF NKX019, AN ALLOGENEIC CAR NK FOR THE TREATMENT OF RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES', HemaSphere, 7, pp. e37234fb - e37234fb, http://dx.doi.org/10.1097/01.hs9.0000967956.37234.fb
,2023, 'American Society of Transplantation and Cellular Therapy International Affair Committee: Report of the Third Workshop on Global Perspective to Access to Transplantation at the 2022 Tandem Meeting', Transplantation and Cellular Therapy, 29, pp. 410 - 417, http://dx.doi.org/10.1016/j.jtct.2023.02.024
,2023, 'Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis', Haematologica, 108, pp. 1900 - 1908, http://dx.doi.org/10.3324/haematol.2022.281958
,2023, 'The need to accelerate COVID-19 education across medical schools', International journal of medical education, 14, pp. 75 - 76, http://dx.doi.org/10.5116/ijme.6488.1a6e
,2023, 'Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE)', Bone Marrow Transplantation, 58, pp. 659 - 666, http://dx.doi.org/10.1038/s41409-023-01924-6
,2023, 'Immunochemotherapy for life-threatening haematological malignancies in pregnancy: a systematic review of the literature and cross-sectional analysis of clinical trial eligibility', The Lancet Haematology, 10, pp. e458 - e467, http://dx.doi.org/10.1016/S2352-3026(23)00059-5
,2023, 'Incidence of Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease and Treatment with Defibrotide in Allogeneic Transplantation: A Multicenter Australasian Registry Study', Transplantation and Cellular Therapy, 29, pp. 383.e1 - 383.e10, http://dx.doi.org/10.1016/j.jtct.2023.03.014
,2023, 'Outcomes of human immunodeficiency virus-associated Burkitt lymphoma and diffuse large B-cell lymphoma treated in Australia: A report from the Australasian Lymphoma Alliance', British Journal of Haematology, 201, pp. 865 - 873, http://dx.doi.org/10.1111/bjh.18704
,2023, 'The clinical features, management and outcomes of lymphoma in pregnancy: A multicentre study by the Australasian Lymphoma Alliance', British Journal of Haematology, 201, pp. 887 - 896, http://dx.doi.org/10.1111/bjh.18727
,2023, 'Characteristics and Outcomes of Older Patients With Classical Hodgkin Lymphoma: An Australasian Lymphoma Alliance, and Lymphoma and Related Diseases Registry Study', Clinical Lymphoma, Myeloma and Leukemia, 23, pp. 370 - 378, http://dx.doi.org/10.1016/j.clml.2023.01.014
,2023, 'An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia', Transplantation and Cellular Therapy, 29, pp. 279.e1 - 279.e10, http://dx.doi.org/10.1016/j.jtct.2022.12.013
,2023, 'Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry', European Journal of Haematology, 110, pp. 386 - 395, http://dx.doi.org/10.1111/ejh.13915
,2023, 'Global representation among journal editors in haematology: are we diverse, equitable, and inclusive?', The Lancet Haematology, 10, pp. e246 - e247, http://dx.doi.org/10.1016/S2352-3026(23)00069-8
,2023, 'Rates of Menstrual History-Taking and Counseling With Anticancer Treatments Are Low: People Who Menstruate Deserve Gender-Specific Cancer Care', JNCCN Journal of the National Comprehensive Cancer Network, 21, pp. 366 - 372, http://dx.doi.org/10.6004/jnccn.2022.7255
,2023, 'Allogeneic haemopoietic cell transplant services in Australia and New Zealand in the first year of the COVID-19 pandemic: a report from Australia and New Zealand transplant and cellular therapies', Internal Medicine Journal, 53, pp. 323 - 329, http://dx.doi.org/10.1111/imj.15886
,2023, 'A Multicenter, Retrospective Study Evaluating Clinical Outcomes of Ruxolitinib Therapy In Heavily Pretreated Chronic GVHD Patients With Steroid Failure', Transplantation and Cellular Therapy, 29, pp. 120.e1 - 120.e9, http://dx.doi.org/10.1016/j.jtct.2022.11.025
,2023, 'Structural racism in clinical research limits its validity and applicability', The Lancet Haematology, 10, pp. e85 - e86, http://dx.doi.org/10.1016/S2352-3026(23)00001-7
,2023, 'Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) position statement: COVID-19 management in patients with haemopoietic stem cell transplant and chimeric antigen receptor T cell', Internal Medicine Journal, 53, pp. 119 - 125, http://dx.doi.org/10.1111/imj.15978
,2023, 'Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry', Leukemia and Lymphoma, 64, pp. 621 - 627, http://dx.doi.org/10.1080/10428194.2022.2157676
,2023, 'Capturing the lived experiences of women with lymphoma in pregnancy: a qualitative study', Leukemia and Lymphoma, 64, pp. 319 - 328, http://dx.doi.org/10.1080/10428194.2022.2148376
,2023, '2106P Safety and patient reported outcomes of SARS-CoV-2 vaccination in patients with cancer', Annals of Oncology, 34, pp. S1104 - S1104, http://dx.doi.org/10.1016/j.annonc.2023.09.888
,2023, 'First in human data of NKX019, an allogeneic CAR NK for the treatment of relapsed/refractory (R/R) B‐cell malignancies', Hematological Oncology, 41, pp. 526 - 527, http://dx.doi.org/10.1002/hon.3164_389
,2023, 'Glofitamab plus R‐CHOP or polatuzumab vedotin‐R‐CHP is deliverable with high overall response in patients ≤65 years of age with high‐risk DLBCL: Interim analysis of COALITION', Hematological Oncology, 41, pp. 421 - 422, http://dx.doi.org/10.1002/hon.3164_309
,2023, 'POLATUZUMAB, BENDAMUSTINE & RITUXIMAB EFFICACY IN RELAPSED/REFRACTORY TRIAL‐INELIGIBLE LARGE B CELL LYMPHOMA PATIENTS: AN AUSTRALIAN LYMPHOMA REGISTRY (LARDR) STUDY', Hematological Oncology, 41, pp. 718 - 719, http://dx.doi.org/10.1002/hon.3165_572
,2022, 'Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry', BMC Medical Research Methodology, 22, http://dx.doi.org/10.1186/s12874-022-01728-0
,2022, 'An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia', Blood, 140, pp. 8146 - 8149, http://dx.doi.org/10.1182/blood-2022-158338
,2022, 'Characteristics and Outcomes of Elderly Patients with Classical Hodgkin Lymphoma (cHL): An Australian Lymphoma Alliance (ALA), and Lymphoma and Related Disease Registry (LaRDR) Study', Blood, 140, pp. 9413 - 9415, http://dx.doi.org/10.1182/blood-2022-156782
,2022, 'Ibrutinib for Steroid Refractory Chronic Graft Vs Host Disease - Real World Experience', Blood, 140, pp. 10537 - 10539, http://dx.doi.org/10.1182/blood-2022-168683
,2022, 'Time-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with TP53 Mutated and Btki-Refractory Disease: First Report of the Tarmac Study', Blood, 140, pp. 181 - 183, http://dx.doi.org/10.1182/blood-2022-160459
,2022, 'Breakthrough COVID-19 infections in patients with cancer from a prospective study of COVID-19 vaccine response', ANNALS OF ONCOLOGY, 33, pp. 1544 - 1544, http://dx.doi.org/10.1016/j.annonc.2022.10.312
,2022, 'Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis', American Journal of Hematology, 97, pp. 1464 - 1477, http://dx.doi.org/10.1002/ajh.26654
,2022, 'Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis', Internal Medicine Journal, 52, pp. 1826 - 1830, http://dx.doi.org/10.1111/imj.15926
,2022, 'Clinical determinants of SARS-CoV-2 vaccine response in adults with cancer', ANNALS OF ONCOLOGY, 33, pp. S1279 - S1279, http://dx.doi.org/10.1016/j.annonc.2022.07.1704
,2022, 'COVID-19 Vaccine Hesitancy in Australian Patients with Solid Organ Cancers', Vaccines, 10, http://dx.doi.org/10.3390/vaccines10091373
,2022, 'Diagnosis and management of primary central nervous system lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance', Internal Medicine Journal, 52, pp. 1624 - 1632, http://dx.doi.org/10.1111/imj.15658
,2022, 'Diffuse large B-cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance', Internal Medicine Journal, 52, pp. 1609 - 1623, http://dx.doi.org/10.1111/imj.15533
,2022, 'Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study', Clinical Lymphoma, Myeloma and Leukemia, 22, pp. 483 - 494, http://dx.doi.org/10.1016/j.clml.2021.12.016
,2022, 'First, do no harm: the neglect of female genital disease following haematopoietic stem-cell transplantation', The Lancet Haematology, 9, pp. e476 - e477, http://dx.doi.org/10.1016/S2352-3026(22)00186-7
,2022, 'P1573: VARIATION IN USE OF IMMUNOGLOBULIN AND IMPACT ON SURVIVAL IN MULTIPLE MYELOMA: A REPORT FROM THE AUSTRALIA/NEW ZEALAND (ANZ) AND ASIA-PACIFIC (APAC) MYELOMA AND RELATED DISEASES REGISTRIES (MRDR)', HemaSphere, 6, pp. 1454 - 1455, http://dx.doi.org/10.1097/01.hs9.0000849148.93868.54
,2022, 'High-dose chemotherapy for relapsed germ cell tumours: outcomes in low-volume specialized centres', BJU International, 130, pp. 5 - 16, http://dx.doi.org/10.1111/bju.15648
,2022, 'Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement', Pathology, 54, pp. 389 - 398, http://dx.doi.org/10.1016/j.pathol.2022.03.002
,2022, 'Serious Underlying Medical Conditions and COVID-19 Vaccine Hesitancy: A Large Cross-Sectional Analysis from Australia', Vaccines, 10, http://dx.doi.org/10.3390/vaccines10060851
,2022, 'The improvement in overall survival from unrelated donor transplantation in Australia and New Zealand is driven by a reduction in non-relapse mortality: A study from the ABMTRR', Bone Marrow Transplantation, 57, pp. 982 - 989, http://dx.doi.org/10.1038/s41409-022-01683-w
,2022, 'One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors', Haematologica, 107, pp. 1045 - 1053, http://dx.doi.org/10.3324/haematol.2021.279189
,2022, 'Telemedicine for rural and regional patient access to haematology services during the COVID-19 pandemic in Australia', The Lancet Haematology, 9, pp. e325 - e326, http://dx.doi.org/10.1016/S2352-3026(22)00110-7
,2022, 'Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients', Blood, 139, pp. 2499 - 2511, http://dx.doi.org/10.1182/blood.2021014506
,2022, 'Iron deficiency in women: clearing the rust of silence', The Lancet Haematology, 9, pp. e247 - e248, http://dx.doi.org/10.1016/S2352-3026(22)00079-5
,2022, 'Not all mismatches are equal: importance of alloreactivity direction', Haematologica, 107, pp. 787 - 789, http://dx.doi.org/10.3324/haematol.2021.279587
,